- Home
- GTEC vs MDXH Comparison
GTEC vs MDXH Comparison
Compare GTEC & MDXH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | GTEC | MDXH |
|---|---|---|
| Founded | 2006 | 2003 |
| Country | United States | Belgium |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | |
| Sector | Industrials | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 16.0M | 18.5M |
| IPO Year | 2018 | 2021 |
Fundamental Metrics
Financial Performance| Metric | GTEC | MDXH |
|---|---|---|
| Price | $0.64 | $0.19 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 6 |
| Target Price | N/A | ★ $0.83 |
| AVG Volume (30 Days) | 224.9K | ★ 1.5M |
| Earning Date | 11-06-2026 | 11-12-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.35 | N/A |
| Revenue | ★ $90,694,007.00 | N/A |
| Revenue This Year | $8.06 | $6.81 |
| Revenue Next Year | N/A | $13.37 |
| P/E Ratio | $1.79 | ★ N/A |
| Revenue Growth | ★ 8.04 | N/A |
| 52 Week Low | $0.47 | $0.17 |
| 52 Week High | $1.61 | $5.24 |
Technical Indicators
Market Signals| Indicator | GTEC | MDXH |
|---|---|---|
| Relative Strength Index (RSI) | 35.77 | 24.51 |
| Support Level | $0.50 | $0.17 |
| Resistance Level | $0.73 | $0.66 |
| Average True Range (ATR) | 0.07 | 0.05 |
| MACD | -0.00 | -0.03 |
| Stochastic Oscillator | 24.14 | 4.21 |
Price Performance
Historical ComparisonAbout GTEC Greenland Technologies Holding Corporation
Greenland Technologies Holding Corp is a developer of quality solutions in the material handling industry. It is a transmission and drivetrain systems provider for material handling equipment such as forklift trucks for industrial and logistic applications. Geographically, the company has its presence in Domestic and International markets and earns majority of the revenue from Domestic Sales.
About MDXH MDxHealth SA
MDxHealth SA is a multinational healthcare company that provides actionable molecular diagnostic information to personalize the diagnosis and treatment of cancer. Its tests are based on proprietary genomic, epigenetic, and other molecular technologies and assist physicians with the diagnosis of urologic cancers, the prognosis of recurrence risk, and the prediction of response to a specific therapy. It derives revenues from clinical laboratory service testing or the out-licensing of the company's patented DNA methylation platform and biomarkers. Geographically, it derives revenue from the United States of America (USA) and Europe.